| Revenue Growth | Q3 revenue $7.3M up 75%; nine-month revenue $21.3M up 99%. |
|---|---|
| Mgmt Confidence | Confident in US strategy but cautious on Middle East shipment timing. |
| Demand Visibility | Expanded pipeline of qualified opportunities; 25 scanners expected sold in Q4. |
| Order Book | Backlog includes delayed Middle East shipments and growing US hospital pipeline. |
| Margin Trends | Gross margin 41.3%; US scanner margins 41%, international margins higher. |
| Op. Leverage | Relocated to 22,000 sq ft facility, doubling capacity while reducing lease costs. |
| Vol vs Price | Growth driven by volume; 15 scanners sold vs 9 last year. |
| Segment Growth | US commercial business gaining momentum; Middle East shipments delayed by conflict. |
| New Clients | National GPO agreement with Premier Inc. covering 4,400 hospitals. |
| Capex & Debt | Cash balance approximately $8M; no immediate plans for capital raise. |
| Regulatory | CMS established Medicare payment for diagnostic QT scans effective January 2027. |
| Commentary | Shift from women adapting to technology to technology adapting to women. |
| New Launches | Commercial expansion into Israel, Bahrain, Qatar, and American Hospital Dubai. |
Growth
Q3 revenue grew 75% to $7.3M; scanner sales increased from 9 to 15 units.
Outlook
Guiding to $34M revenue for 2026; targeting 25% revenue growth in 2027.
Risks
Management lowered 2026 revenue guidance by $5M due to Middle East conflict and shipping disruptions.
The company's earnings call, NASDAQ: QTI, and its 8-K filed with the SEC. Summary written with AI assistance from the call.
Earnings call webcast ↗ Watch on YouTube ↗
Qt Imaging Holdings, Inc.: key numbers
- Share price
- $1.80Close, Nov 16
- Market cap
- $26.4M
- Shares outstanding
- 14.69MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Electromedical & Electrotherapeutic ApparatusSIC 3845
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Qt Imaging Holdings, Inc.
All →Qt Imaging Holdings Investor Presentation
QT Imaging Holdings, Inc. has published an updated investor presentation to its website and filed it with the SEC. The presentation provides supplemental product and operational information regarding the company's Breast Acoustic CT Scanner technology. The filing is intended to provide current and potential investors with strategic highlights and technical details of the company's imaging platform.
Qt Imaging Holdings Q3 2026 Results: Net Loss of $297K, Loss Narrows
QT Imaging Holdings reported significant revenue growth for the nine months ended September 30, 2026, reaching $21.3 million compared to $10.7 million in 2025. Despite this, the company incurred a net loss of $14.8 million, driven by increased operating expenses and a $8.3 million loss on debt extinguishment and modification.
- Key figure
- Net loss $297K
Qt Imaging Holdings Financial Results
QT Imaging reported Q3 2026 revenue of $7.3 million, a 75% year-over-year increase, driven by the sale of 15 Breast Acoustic CT scanners. The company achieved a major regulatory milestone with CMS establishing a Medicare hospital outpatient payment pathway for diagnostic QTscan examinations effective January 1, 2027. Full-year 2026 revenue guidance was adjusted to approximately $34 million due to international shipment delays caused by conflict in the Middle East.
- Term
- Q3 2026
“Our third-quarter results demonstrate the continued growth of QT Imaging, with revenue increasing 75% year over year and reaching $21.3 million for the first nine months of 2026, approximately double the prior-year period.”
Dr. Raluca Dinu, Chief Executive Officer of QT Imaging
“A major milestone is the recent CMS decision establishing separate Medicare hospital outpatient payment for medically necessary diagnostic QTscan examinations, effective January 1, 2027. Together with our dedicated billing code, effective October 1, this decision removes a significant reimbursement uncertainty and strengthens our ability to expand into U.S. hospitals and health systems.”
Dr. Raluca Dinu, Chief Executive Officer of QT Imaging